In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vernalis Group PLC

Division of Ligand Pharmaceuticals Inc.
www.vernalis.com

Latest From Vernalis Group PLC

European IPOs Hold Their Own

The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists. The wisdom's changed (or some of it, anyway).
BioPharmaceutical Europe

Europe's Flavors of Sustainable BioPharma

Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging--mostly through the transformation of existing pharma assets.
BioPharmaceutical Europe

Celltech-UCB: UK's Loss Could be Mid-Sized Pharma's Gain

Celltech's shareholders should be delighted with the price of UCB's acquisition, since the company probably could not have otherwise secured the kind of alliance it wanted for its flagship product. But UK biotech has sustained a severe blow, losing its only truly liquid biotech. Meanwhile, in suggesting that late-stage deal prices may be reaching their upper limits, the deal sends a wake-up call to other mid-sized European pharma. It's time to leverage shareholder, cash and size differences with Big Pharma to recast Euro-focused primary-care operations into higher profit, albeit higher risk, specialist businesses.
BioPharmaceutical Europe

Antibacterials: Biotechs Fill the Big Pharma Void

Big Pharma may have abandoned anti-bacterial research some years ago, but biotechs are filling the void. Their approaches range from improving existing drugs to discovering entirely new targets. Yet although a handful in Europe, including recently floated Basilea and private firm Arrow, has attracted recent investor interest, it hasn't been the anti-bacterials per se that have drawn them in. Basilea benefited from its spin-off status; Arrow from a promising anti-viral project and broad portfolio. Despite growing concerns over bacterial resistance, the field needs success stories to draw investors back for good. Even then, the nature of the diseases and therapies under development mean it's likely to remain the domain of smaller firms.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Vanguard Medica Group PLC
  • Vernalis Group PLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Ligand Pharmaceuticals Inc.
  • Senior Management
  • Peter Worrall, CEO
    Colin T Dourish, SVP, Research
  • Contact Info
  • Vernalis Group PLC
    Phone: (44) 118 977 3133
    Oakdene Ct. 613 Reading Rd.
    Winnersh, RG41 5UA
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register